Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Senate Medicare Vote Suggests $400 Bil. Rx Benefit Is Winning Formula

Executive Summary

The magic number in the Medicare prescription drug coverage debate appears to be $400 bil. over 10 years

You may also be interested in...



CMS “Functional Equivalence” Standard Targeted In Medicare Bills

CMS would be prohibited from using the Aranesp/ Procrit "functional equivalence" decision as a precedent in future reimbursement rulings under both the House and Senate versions of the Medicare prescription drug bill

Medicare Rx Card: Will Drug Discounts Be Permanent Program Fixture?

The role of a Medicare prescription drug discount card will be worked out between the House Energy & Commerce and Ways & Means Committees before a single Medicare bill comes to the floor for a vote

CMS “Functional Equivalence” Standard Targeted In Medicare Bills

CMS would be prohibited from using the Aranesp/ Procrit "functional equivalence" decision as a precedent in future reimbursement rulings under both the House and Senate versions of the Medicare prescription drug bill

Related Content

UsernamePublicRestriction

Register

ID005817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel